Covered recipient · General Payments record
LUV PATEL
Allopathic & Osteopathic Physicians Ophthalmology Retina Specialist
General Payments · PY2018–2024
$3,344.27
- Reported across 60 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $417.06 | 16 |
| Education | $20.73 | 1 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $126.38 | 5 |
| Sandoz Inc. | $104.59 | 4 |
| Genentech USA, Inc. | $53.49 | 2 |
| Apellis Pharmaceuticals, Inc. | $50.75 | 2 |
| Regeneron Healthcare Solutions, Inc. | $44.69 | 2 |
| Astellas Pharma US Inc | $30.88 | 1 |
| Coherus Biosciences Inc. | $27.01 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $28.48 | 02/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105196382 | CMS |
| ABBVIE INC. | $23.23 | 04/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105196384 | CMS |
| ABBVIE INC. | $28.09 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105196386 | CMS |
| ABBVIE INC. | $22.40 | 09/27/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105196388 | CMS |
| ABBVIE INC. | $24.18 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105196390 | CMS |
| Apellis Pharmaceuticals, Inc. | $26.72 | 02/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154025253 | CMS |
| Apellis Pharmaceuticals, Inc. | $24.03 | 05/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1154025255 | CMS |
| Astellas Pharma US Inc | $30.88 | 05/31/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139371101 | CMS |
| Coherus Biosciences Inc. | $27.01 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147274108 | CMS |
| Genentech USA, Inc. | $25.17 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133057213 | CMS |
| Genentech USA, Inc. | $28.32 | 11/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133057217 | CMS |
| Regeneron Healthcare Solutions, Inc. | $23.96 | 03/02/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1114132574 | CMS |
| Regeneron Healthcare Solutions, Inc. | $20.73 | 08/22/2024 | Education | Undisputed | 01/23/2026 | 1114132576 | CMS |
| Sandoz Inc. | $27.79 | 03/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089368386 | CMS |
| Sandoz Inc. | $27.87 | 10/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089368444 | CMS |
| Sandoz Inc. | $22.61 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089368442 | CMS |
| Sandoz Inc. | $26.32 | 10/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1089368446 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.